A descriptive cross-sectional study of self-management in patients with nonvalvular atrial fibrillation

Medicine (Baltimore). 2022 Oct 7;101(40):e30781. doi: 10.1097/MD.0000000000030781.

Abstract

Self-management of non-valvular atrial fibrillation (NVAF) is characterized by complexity and diversity of content. Inadequate self-management exposes patients to the risk for complications such as stroke and bleeding. To assess the status and predictors of self-management in NVAF patients, a descriptive cross-sectional study was conducted. The self-management scales for atrial fibrillation were used to assess the status of self-management of patients who received Warfarin, NOAC, Aspirin, or No anticoagulant therapy. The general situation questionnaire was used to collect socio-demographic and clinical data from patients. A total of 555 participants completed the survey, with self-management score of 71.21 ± 12.33, 69.59 ± 13.37, 69.03 ± 12.20 and 66.12 ± 11.36 in Warfarin group, NOAC group, Aspirin group and No anticoagulant group, respectively. In Warfarin group lower educational status was associated with poor self-management; in Aspirin group, comorbidities and age < 65 years (P = .001) were associated with poor self-management; in No anticoagulant group, age < 65 years, single, poor sleep quality, and permanent AF were associated with poor self-management. Self-management was inadequate in patients with NVAF. Poor self-management might be related with the occurrence of cerebral embolism. For NVAF patients receiving anti-thrombotic therapy, relatively young age, comorbidities, and age can have a substantial impact on self-management performance; while age, type of AF, quality of sleep, married status are associated with self-management in patients with no anticoagulants.

MeSH terms

  • Aged
  • Anticoagulants / therapeutic use
  • Aspirin / therapeutic use
  • Atrial Fibrillation* / complications
  • Cross-Sectional Studies
  • Humans
  • Self-Management*
  • Stroke* / epidemiology
  • Stroke* / etiology
  • Stroke* / prevention & control
  • Warfarin / therapeutic use

Substances

  • Anticoagulants
  • Warfarin
  • Aspirin